West Nile virus envelope protein domain III (WNV E-DIII)

The West Nile virus (WNV) envelope (E) protein domain III (DIII) is a discrete, immunoglobulin-like fold located at the distal end of the E protein monomer on the viral surface (Nybakken et al., 2005). It plays a pivotal role in the viral life cycle by mediating attachment to host cell receptors, which is the initial step of infection (Beasley & Barrett, 2002). DIII is the primary target for the most potent neutralizing antibodies, such as E16, which bind to the highly conserved lateral face of the domain (Oliphant et al., 2005). These antibodies neutralize the virus by blocking receptor engagement and preventing the pH-dependent conformational changes required for membrane fusion (Pierson et al., 2008). Because DIII-specific antibodies are generally less likely to induce antibody-dependent enhancement (ADE) compared to those targeting the fusion loop in domain II, DIII is considered a safer and more effective target for vaccine and therapeutic development (Sultana et al., 2009). Therapeutic strategies include the use of humanized monoclonal antibodies like MGAWN1 and the development of recombinant protein or DNA vaccines that focus the immune response on these critical neutralizing epitopes. This domain's structural stability and accessibility make it an ideal candidate for diagnostic assays and targeted antiviral therapies.

Other names

West Nile virus E protein domain IIIWNV ED3WNV E-DIIIWest Nile virus envelope protein domain 3West Nile virus envelope protein domain III and related neutralizing epitopes

Neutralization of viral infectivity by blocking receptor binding and inhibiting post-attachment steps such as membrane fusion.